glp 1 2 and 3 GLP-1 Receptor Agonists as Treatments for Type Diabetes Triple Agonism Based Therapies for
Description
doi:10.1530/JOE-16-0598 46
Following its approval by the FDA in 2022 for the treatment of T2DM (19, 24)
180,181,183 GLP-1 also activates the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway, which is crucial for maintaining the survival and function of pancreatic -cells
E., Gishan, F
